• DOI:10.1136/bmj.e6629
Corpus ID: 38748244

FDA given new powers over data reporting to national clinical trials registry

@article{Roehr2012FDAGN,
  title={FDA given new powers over data reporting to national clinical trials registry},
  author={B. Roehr},
  journal={BMJ : British Medical Journal},
  year={2012},
  volume={345}
}

B. Roehr

Published 2012

Medicine

BMJ : British Medical Journal

The US Food and Drug Administration (FDA) has been given the authority to monitor and enforce the reporting of required data to the national clinical trials registry (ClinicalTrials.gov). Authority for the registry previously rested with the Secretary of Health but was transferred to the FDA on 26 September.1 The move is seen as a streamlining or rationalization of administrative responsibilities and will probably result in enhanced accountability. The National Institute for Health’s (NIH… CONTINUE READING

View on BMJ

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed